Recent Updates
Recently added Catalysts
ACRS

Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017

Key Takeaway: MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and pro

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Last updated: May 9, 2017